Jack Peurach - Ekso Bionics Independent Director
| EKSO Stock | USD 1.18 0.02 1.72% |
Director
Mr. Jack Peurach is President, Chief Executive Officer, Director of the Company. Prior to joining Ekso Bionics, Mr. Peurach was the Executive Vice President, Products for SunPower Corporationration, where he was responsible for all aspects of SunPower PV modules and residential, commercial and utility PV systems. From 2009 to 2011, Mr. Peurach served as Executive Vice President, Research and Development for SunPower, where he led the research and development efforts of the PV Cells, Modules and Systems since 2018.
| Age | 48 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 101 Glacier Point, San Rafael, CA, United States, 94901 |
| Phone | 510 984 1761 |
| Web | https://www.eksobionics.com |
Ekso Bionics Management Efficiency
The company has return on total asset (ROA) of (0.2706) % which means that it has lost $0.2706 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7989) %, meaning that it created substantial loss on money invested by shareholders. Ekso Bionics' management efficiency ratios could be used to measure how well Ekso Bionics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of April 2024, Return On Tangible Assets is likely to drop to -0.68. In addition to that, Return On Capital Employed is likely to drop to -0.76. At this time, Ekso Bionics' Total Current Assets are very stable compared to the past year. As of the 25th of April 2024, Non Currrent Assets Other is likely to grow to about 504.2 K, while Total Assets are likely to drop about 26 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Carsten Hellmann | Coloplast A | 53 | |
| William Farrell | Pro Dex | 44 | |
| Thomas Barfod | Coloplast A | 53 | |
| Pablo Cardenas | Milestone Scientific | 39 | |
| Birgitte Nielsen | Coloplast A | 54 | |
| James Beeson | Utah Medical Products | 75 | |
| Per Magid | Coloplast A | 73 | |
| Raymond Cabillot | Pro Dex | 54 | |
| John OConnor | LeMaitre Vascular | 70 | |
| Caroline Rosenstand | Coloplast A | N/A | |
| Beat Luethi | Straumann Holding AG | 56 | |
| Edward Zelnick | Milestone Scientific | 68 | |
| Alfred Vargas | Nephros | N/A | |
| Matthew Rosenberg | Nephros | 33 | |
| Barbara Payne | Utah Medical Products | 70 | |
| Alisa Lask | Nephros | N/A | |
| Wayne Yetter | InfuSystems Holdings | 71 | |
| Giovannella Deiure | LeMaitre Vascular | 49 | |
| Daniel Mumford | LeMaitre Vascular | 42 | |
| Neal Goldman | Milestone Scientific | 74 | |
| Ernst Hoyer | Utah Medical Products | 79 | |
Management Performance
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.27 |
Ekso Bionics Holdings Leadership Team
Elected by the shareholders, the Ekso Bionics' board of directors comprises two types of representatives: Ekso Bionics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ekso. The board's role is to monitor Ekso Bionics' management team and ensure that shareholders' interests are well served. Ekso Bionics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ekso Bionics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Maximilian SchederBieschin, CFO | ||
| Howard Palefksy, Director | ||
| Dan Boren, Independent Director | ||
| Steven Sherman, Chairman of the Board | ||
| Stanley Stern, Independent Director | ||
| Rachael Anderson, Global Growth | ||
| Russ Angold, Co-Founder and President of Ekso Labs Division | ||
| Jason Jones, Chief Officer | ||
| John Glenn, CFO, Secretary | ||
| Bill Shaw, Chief Commercial Officer | ||
| Foon Chwee, President APAC | ||
| Scott Davis, Chief Officer | ||
| Jerome Wong, Corporate Controller | ||
| Stephan Aderhold, Senior EMEA | ||
| Theodore Wang, Director | ||
| Amy Wendell, Director | ||
| Jack Peurach, Independent Director | ||
| Russdon Angold, CTO | ||
| Thomas Looby, Pres and Chief Commercial Officer | ||
| Ann Cookson, Human Director | ||
| Marilyn Hamilton, Independent Director | ||
| Matthias Stief, Managing Director | ||
| Charles Li, Director | ||
| Thomas Schreck, Director | ||
| Nathan Harding, Co-Founder, CEO and Director | ||
| Ted Wang, Director | ||
| Anthony Pratt, Vice Sales |
Ekso Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ekso Bionics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (0.83) % | ||||
| Operating Margin | (0.71) % | ||||
| Current Valuation | 21.45 M | ||||
| Shares Outstanding | 17.9 M | ||||
| Shares Owned By Insiders | 13.00 % | ||||
| Shares Owned By Institutions | 7.61 % | ||||
| Number Of Shares Shorted | 134.27 K | ||||
| Price To Earning | (0.67) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Ekso Bionics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Ekso Bionics' short interest history, or implied volatility extrapolated from Ekso Bionics options trading.
Pair Trading with Ekso Bionics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ekso Bionics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ekso Bionics will appreciate offsetting losses from the drop in the long position's value.Moving against Ekso Stock
| 0.85 | AGTI | Agiliti Financial Report 14th of May 2024 | PairCorr |
| 0.8 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.77 | DSGN | Design Therapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.73 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.62 | NXL | Nexalin Technology | PairCorr |
The ability to find closely correlated positions to Ekso Bionics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ekso Bionics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ekso Bionics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ekso Bionics Holdings to buy it.
The correlation of Ekso Bionics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ekso Bionics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ekso Bionics Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ekso Bionics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ekso Bionics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Ekso Stock analysis
When running Ekso Bionics' price analysis, check to measure Ekso Bionics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ekso Bionics is operating at the current time. Most of Ekso Bionics' value examination focuses on studying past and present price action to predict the probability of Ekso Bionics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ekso Bionics' price. Additionally, you may evaluate how the addition of Ekso Bionics to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Ekso Bionics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ekso Bionics. If investors know Ekso will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ekso Bionics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.10) | Revenue Per Share 1.318 | Quarterly Revenue Growth 0.365 | Return On Assets (0.27) | Return On Equity (0.80) |
The market value of Ekso Bionics Holdings is measured differently than its book value, which is the value of Ekso that is recorded on the company's balance sheet. Investors also form their own opinion of Ekso Bionics' value that differs from its market value or its book value, called intrinsic value, which is Ekso Bionics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ekso Bionics' market value can be influenced by many factors that don't directly affect Ekso Bionics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ekso Bionics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ekso Bionics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ekso Bionics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.